Summit Biosciences Announces the Addition of Ted A. Marcuccio to its Senior Management Team
LEXINGTON, Ky., June 7, 2017 /PRNewswire/ - Summit Biosciences Inc. announced today that Ted A. Marcuccio has been appointed Chief Business Officer. He will be responsible for cultivating strategic alliances to facilitate the further development and commercialization of Summit's portfolio and pipeline and promoting the company's continued growth in the market for prescription and over-the-counter nasal spray products.
Mr. Marcuccio has over 15 years of executive experience with leading companies in the pharmaceutical industry. He has played an instrumental role in a wide range of corporate transactions as a business development executive and former investment banker. He has a vast network of contacts in the healthcare and life sciences industry and strong relationships in the capital markets.
"Ted Marcuccio brings to Summit a wealth of relevant experience, expertise and relationships that will help the company bring new nasal products to market," said Edwin Cohen, Summit's Founder, Chairman and Chief Executive Officer. "Summit has a proven capability to develop and manufacture prescription nasal spray products that patients, doctors, and insurers find increasingly attractive and affordable in delivering medicines for chronic and emergency use," said Mr. Marcuccio. "I am excited for the opportunity to join Summit's leadership team to help drive the next phase of the company's growth in the global pharmaceutical market."
Most recently, Mr. Marcuccio led government and commercial development and alliance management for Meridian Medical Technologies, Inc., a subsidiary of Pfizer Inc., which specialized in emergency use pharmaceuticals delivered with its proprietary auto-injector technology. He was Vice President and Head of Licensing and Business Development for Meridian's former parent company, King Pharmaceuticals, Inc., until its acquisition by Pfizer in 2011. Previous to joining King in 2004, he was Vice President of Vaccines Business Development for Baxter International.
Summit Biosciences Inc. (www.summitbiosciences.com) is a privately-held specialty pharmaceutical company that develops, manufactures and commercializes prescription and innovative nasal spray products. The company has approved and development-stage products across a range of indications. The company's headquarters and base of operations are in Lexington, KY.
CONTACT: Greg Plucinski, Chief Operating Officer (859) 254-0180 x 233